<abstract xmlns="http://www.w3.org/1999/xhtml">

<p><italic>Neisseria gonorrhoeae</italic> is an aetiological agent of gonorrhoea, which is a sexually transmitted disease (STD), a public health challenge worldwide. Gonorrhoea is undoubtedly a serious health risk, especially for women, due to its often asymptomatic course and the possibility of upper genital tract complications such as pelvic inflammatory disease (PID), which can result in infertility. The data show that the diagnostic method for <italic>N. gonorrhoeae</italic> should be specific, simple, sensitive, rapid and inexpensive. Currently, phenotypic identification methods have been dominated by NAAT methods, which allow detection and identification of gonococcus directly in the clinical specimen. However, up today molecular methods do not allow full determination of drug susceptibility.</p>
</abstract>

Neisseria gonorrhoeae is an aetiological agent of gonorrhoea, which is a sexually transmitted disease (STD), a public health challenge worldwide. Gonorrhoea is undoubtedly a serious health risk, especially for women, due to its often asymptomatic course and the possibility of upper genital tract complications such as pelvic inflammatory disease (PID), which can result in infertility. The data show that the diagnostic method for N. gonorrhoeae should be specific, simple, sensitive, rapid and inexpensive. Currently, phenotypic identification methods have been dominated by NAAT methods, which allow detection and identification of gonococcus directly in the clinical specimen. However, up today molecular methods do not allow full determination of drug susceptibility.

Gonococci – Pathogens of Growing Importance. Part 1. Current Data on Diagnostics, Genotyping and Therapy.

Advancements of Microbiology

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Neisseria gonorrhoeae is an aetiological agent of gonorrhoea, which is a sexually transmitted disease (STD), a public health challenge worldwide. Gonorrhoea is...

Antibiotic (abbreviation)	MIC limit values (mg/l)
	EUCAST v 12.0 2023		CLSI 2020
	≤ W	> O	≤ W	> O
Penicillin (P)	0,06	1,0	0,06	2,0
Cefixime (CFM)	0,125	0,125	0,25	-
Ceftriaxone (CRO)	0,125	0,125	0,25	-
Cefotaxime (CTX)	0,125	0,125	0,5	-
Azithromycin (AZM)*	1,0 (ECOFF)		1,0	-
Ciprofloxacin (CIP)	0,03	0,06	0,06	1,0
Tetracycline (T)	0,5	0,5	0,25	2,0
Spectinomycin (SPT)	64,0	64,0	32,0	128,0

NAAT test detected pathogens	Producer	Method	Molecular targets N. gonorrhoeae
Aptima NG assay N. gonorrhoeae	(Hologic/Gen-Probe, SanDiego, California)	TMA	Specific region of 16S rRNA, different than in the Aptima Combo 2 assay
Aptima Combo 2 assay C. trachomatis, N. gonorrhoeae	(Hologic/Gen-Probe, SanDiego, California)	TMA	Specific region of 16S rRNA
Abbott Real Time 2000 CT/NG C. trachomatis, N. gonorrhoeae	Abbott Molecular Inc. Des Plaines, Illinois	qPCR	48 bp sequence within the Opa gene
Cobas CT/NG C. trachomatis, N. gonorrhoeae	Roche Molecular Diagnostics, Branchburg, New Jersey	PCR	two sequences within the fragment DR 9A and DR 9B (DR – direct repeat)
BD ProbeTec ET CT/GC Ampliefied DNA assay C. trachomatis, N. gonorrhoeae	Becton Dickinson, Sparks, Maryland	SDA	Chromosomal pilin gene-inverting protein homolog
BD ProbeTec NG Q N. gonorrhoeae	Becton Dickinson, Sparks, Maryland	SDA	Chromosomal pilin gene-inverting protein homolog
Xpert CT/NG Assay C. trachomatis, N. gonorrhoeaes	Cepheid, Sunnyvale, California	qPCR	two specific chromosomal DNA sequence

Gonococci – Pathogens of Growing Importance. Part 1. Current Data on Diagnostics, Genotyping and Therapy.

Data publikacji: 25 mar 2024

Zakres stron: 3 - 14

Otrzymano: 01 sty 2024

Przyjęty: 01 lut 2024

DOI: https://doi.org/10.2478/am-2024-0001

Słowa kluczowe
AMR, diagnosis, gonorrhoea, molecular typing, STD

© 2024 Joanna Białecka et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Fig. 1.

MIC breakpoint range for N. gonorrhoeae according to EUCAST recommendations v 12.0 2023.01.01 and CLSI 2020

FDA-approved molecular diagnostic tests for the clinical diagnosis of gonorrhea, based on CDC Recommendations (2014)

Gonococci – Pathogens of Growing Importance. Part 1. Current Data on Diagnostics, Genotyping and Therapy.

Data publikacji: 25 mar 2024

Zakres stron: 3 - 14

Otrzymano: 01 sty 2024

Przyjęty: 01 lut 2024

DOI: https://doi.org/10.2478/am-2024-0001

Słowa kluczoweAMR, diagnosis, gonorrhoea, molecular typing, STD

© 2024 Joanna Białecka et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Fig. 1.

MIC breakpoint range for N. gonorrhoeae according to EUCAST recommendations v 12.0 2023.01.01 and CLSI 2020

FDA-approved molecular diagnostic tests for the clinical diagnosis of gonorrhea, based on CDC Recommendations (2014)

Słowa kluczowe
AMR, diagnosis, gonorrhoea, molecular typing, STD